Navigation Links
The J.M. Smucker Company Travels the U.S. to Launch the Simple Steps To A Better You Campaign
Date:4/24/2008

p make smarter food choices that are also quick and convenient for a variety of lifestyles."

Smucker's Fruit Spreads

During the tour, Smucker's will offer samples and recipe tips for their sugar free, low sugar and natural peanut butter varieties. Smucker's sugar-free fruit spreads allow consumers to enjoy the fresh fruit taste of Smucker's in a product that contains 80 percent fewer calories than regular fruit spreads and zero grams of sugar per serving. Smucker's Low Sugar contains no artificial sweeteners and 50 percent less sugar, calories and carbohydrates than regular fruit spreads. Smucker's offers a wide array of sugar free and Low Sugar flavors and both varieties are fat free.

Smucker's Natural Peanut Butter

Smucker's(R) Natural Peanut Butter is 100 percent natural, made with 99 percent peanuts and just a dash of salt. Just one serving of peanut butter -- two tablespoons -- provides eight grams of protein, two grams of fiber, 10 percent of the USDA Reference Daily Intake (RDI) of vitamin E and 12 percent of the RDI of magnesium. Smucker's Natural Peanut Butter is a cholesterol free food and contains zero grams of trans-fats per serving. Available in five different varieties -- Creamy, Chunky, With Honey, No Salt Added and Reduced Fat -- Smucker's Natural Peanut Butter offers consumers an assortment of choices.

Consumers are encouraged to visit http://www.smuckers.com/simplesteps to learn more about the Simple Steps To A Better You Tour and to see the tour schedule. On the site, consumers can also find out how to receive a Smucker's stability workout ball (while supplies last), free work-out music downloads, a workout log, Denise's fitness tips, new recipes and more information about Smucker's Natural Peanut Butter and Smucker's varieties of fruit spreads.

About The J.M. Smucker Company

The J.M. Smucker Company is the leading marketer and manufact
'/>"/>

SOURCE The J.M. Smucker Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Perrigo Company Will Release Third Quarter Fiscal 2008 Results on May 6, 2008
2. Online Job Search Company from Virginia is National Small Business of the Year
3. Eastern Alliance Insurance Group and Eastern Life and Health Insurance Company Announce Affirmation of A- (Excellent) A.M. Best Ratings and a Positive Outlook for Eastern Alliance Insurance Group
4. New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements
5. BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond
6. IPC The Hospitalist Company, Inc. to Report First Quarter 2008 Financial Results
7. Town Health and Ping An Insurance (Group) Company of China, Ltd. Join Forces to Develop and Manage Clinic Chain in Pearl River Delta Area
8. KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation
9. Leading Life Sciences Company Installs SafeMedias Network Security Management Appliance to Prevent Illegal Peer to Peer (P2P) File Sharing
10. $3 Billion Asbestos Deal Reached by W.R.Grace Company to Pay Asbestos Victims
11. Kronos Optimal Health Company Aims to Stop Diabetes Before It Starts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2008)... Dr. Alan Greene from the kids, health w...eating only organic food. It,s the same benchmark ...nic. , Danville, CA (PRWE...certified organic by the Department of Agriculture... Alan Greene, why not people?, , , , ,In an artic...
(Date:12/4/2008)...a, Dec. 5 Health Care ...ay launched a global partnership to substitute mer...d affordable alternatives. , , The announce...nference on Alternatives to Mercury in Health Care...the Indian NGO Toxics Link. , , "This initi...
(Date:12/4/2008)...omen using Carraguard had no decrease in infection...lthDay News) -- A microbicidal vaginal gel called ...n. , That,s the conclusion of a study that incl... women at three sites in South Africa. , The wo...and told to use one applicator of gel and a condom...
(Date:12/4/2008)..., Dec. 4 MiddleBrook,Ph...nced that it has opened its,administrative and sa...antown,facility will continue to house certain pe...search and development group. The newly leased 14... house up to 60 employees as MiddleBrook,grows. ,...
Breaking Medicine News(10 mins):Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 2Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 3Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2Health News:Experimental Vaginal Gel Doesn't Ward Off HIV 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4
...here are certain conditions under which they loose... proteins leading to protein aggregation called as...e for causing neurodegenerative disorders such as ...am from Universitat Autònoma de Barcelona, led by ...
...be effectively fused with other cells to work else...ng to a study.// Researchers at Oregon Health and ...cells may be useful in fighting disease. The rese...Grompe, showed that mice with a disease called tyr...
...Wednesday doctors and hospitals in the global heal...Rs 100 million.// Six hospitals in Chennai, two in... residences of 14 prominent doctors were raided by...Rs.6 million in cash as well as fixed deposits and...
...e responsible for transferring the amino acid Cyst...ucing oxidative stress as Cysteine present in glut...nging activity in brain.// Free radicals are respo...y antioxidants. Professor Raymond Swanson and his ...
Other Medicine News:
(Date:12/3/2008)... potential in newly diagnosed patients with a life...o oral sessions at ASH , , - Exjade results...d patients by significantly reducing toxic iron th...m data from major independent breast cancer trial ...nt strategy, Femara vs. tamoxifen , , - Mul...
(Date:12/3/2008)...irstCall/ -- Wyeth Pharmaceuticals,a division of... submitted a,marketing authorization application ... approval to market its investigational 13-valent ...s and young children. Wyeth is seeking an,indica...D) caused by the 13,serotypes included in the inv...
(Date:12/2/2008)... -- Researchers using functional,MRI (fMRI) have ...rain,responsible for suppressing memory is dysfun... psychiatric disorders. Results of the study will ...adiological Society of North America,(RSNA). , ... stress-related disorders,traumatic memories are...
(Date:12/2/2008)...rizon Therapeutics, Inc., a,privately held biopha...tal,Phase 3 trials evaluating its lead investigat... endpoints. HZT-501, a novel, proprietary fixed-do...amotidine, demonstrated a,statistically significa...ti-inflammatory drug (NSAID)-induced upper gastroi...
Breaking Medicine Technology:More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference 8642 1Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 27859 1Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 27859 2LCA Vision Reports Third Quarter 2008 Financial Results 27857 1LCA Vision Reports Third Quarter 2008 Financial Results 27857 2LCA Vision Reports Third Quarter 2008 Financial Results 27857 3LCA Vision Reports Third Quarter 2008 Financial Results 27857 4LCA Vision Reports Third Quarter 2008 Financial Results 27857 5LCA Vision Reports Third Quarter 2008 Financial Results 27857 6LCA Vision Reports Third Quarter 2008 Financial Results 27857 7LCA Vision Reports Third Quarter 2008 Financial Results 27857 8LCA Vision Reports Third Quarter 2008 Financial Results 27857 9LCA Vision Reports Third Quarter 2008 Financial Results 27857 10LCA Vision Reports Third Quarter 2008 Financial Results 27857 11LCA Vision Reports Third Quarter 2008 Financial Results 27857 12LCA Vision Reports Third Quarter 2008 Financial Results 27857 13Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 1Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 2Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 3
...ON, March 06, 2007 /PRNewswire/ -- Up to two milli...p to 600,000,hospitalized. Its primary complicatio...ives annually -- more than breast cancer and,AIDS ...sease may be,at increased risk for DVT, because th...clots and pooling. Respiratory tract infection,may...
...E, Mass., March 06, 2007 /PRNewswire-FirstCall/ --... three completed,Phase III multi- center clinical ...acement therapeutic will be presented during,the N...al Meetings,taking place April 10th through 14th i...a are scheduled to be presented on,Wednesday, Apri...
Other Medicine Technology:DVT Awareness Survey Findings: Heart and Respiratory Patients 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4
The Estradiol (E2) Enzyme Immunoassay is intended for the for the quantitative determination of Estradiol (E2) concentration in human serum or plasma.
RIA kit for the quantitative determination of autoantibodies to thyroglobulin in serum.
...an 125I radioimmunoassay designed for,in vitro d... estradiol in serum, for the,investigation of pr...n, and for the,differential diagnosis of amenorr...tion,induction with and without stimulation in,...
Coat-A-Count Estradiol is,a no-extraction, solid-phase 125I,radioimmunoassay designed for in vitro,diagnostic use in the quantitative,measurement of estradiol in serum, for the,differential
Medicine Products: